Novo Nordisk's Etavopivat Hits Phase 3 Endpoints for Sickle Cell Disease, Paving Way for H2 2026 Regulatory Submission

summarizeSummary

Novo Nordisk announced positive topline Phase 3 results for etavopivat in sickle cell disease, meeting both co-primary endpoints and demonstrating significant reductions in vaso-occlusive crises and improved haemoglobin response, with regulatory submission planned for the second half of 2026.

check_boxKey Events

• Etavopivat Achieves Phase 3 Success

  Topline results from the HIBISCUS trial showed etavopivat met both co-primary endpoints, significantly reducing vaso-occlusive crises (27% reduction) and improving haemoglobin response (48.7% vs 7.2% placebo) in sickle cell disease patients.

• Regulatory Submission Planned

  Novo Nordisk intends to submit etavopivat for its first regulatory approval in the second half of 2026, following these positive trial outcomes.

• Addresses High Unmet Need

  Etavopivat targets sickle cell disease, a debilitating and life-threatening condition affecting millions globally, where current therapeutic options are limited.

• Pipeline Validation

  This success validates the 2022 acquisition of Forma Therapeutics, from which etavopivat originated, strengthening Novo Nordisk's rare disease pipeline.

auto_awesomeAnalysis

Novo Nordisk announced highly positive Phase 3 results for etavopivat, a drug acquired through the Forma Therapeutics acquisition, in treating sickle cell disease (SCD). Meeting both co-primary endpoints with a significant reduction in vaso-occlusive crises and improved haemoglobin response is a major clinical success. This development is critical for patients with SCD, a severe and life-shortening disease with limited treatment options. The planned regulatory submission in the second half of 2026 positions etavopivat as a potential new blockbuster drug, validating Novo Nordisk's strategic pipeline investments and opening a significant new market opportunity.